Skip to main content
. 2022 Aug 25;67:1604826. doi: 10.3389/ijph.2022.1604826

TABLE 4.

Location of malaria testing and drug consumption, pooled over study arm and the baseline, 12-month and 18-month follow-up waves in Western Kenya 2015–2017.

No test Tested at CHW Tested at private Tested at public
Negative Positive Negative Positive Negative Positive
Observations 3064 85 301 40 597 259 1255
Take AL? 1959 (68.3) 35 (43.8) 294 (98.0) 16 (40.0) 457 (76.9) 118 (45.7) 1135 (90.7)
Drug Combinations
 ACTs with Antibiotics n (%) 399 (13.9) 8 (10.0) 16 (5.3) 12 (30.0) 186 (31.3) 71 (27.5) 418 (33.4)
 ACTs, No Antibiotics n (%) 1595 (55.6) 27 (33.8) 278 (92.7) 4 (10.0) 310 (52.2) 50 (19.4) 737 (58.9)
 Antibiotics, No ACTs n (%) 271 (9.4) 26 (32.5) 0 (0.0) 12 (30.0) 39 (6.6) 107 (41.5) 50 (4.0)
 Neither ACT nor Antibiotics n (%) 604 (21.1) 19 (23.8) 6 (2.0) 12 (30.0) 59 (9.9) 30 (11.6) 47 (3.8)
Total Drug Types Taken (SD) 1.70 (0.75) 1.51 (0.78) 1.95 (0.37) 1.75 (1.10) 2.11 (0.79) 1.99 (0.86)ET 2.27 (0.78)
 Antibiotics (n, %) 670 (23.4) 34 (42.5) 16 (5.3) 24 (60.0) 225 (37.9) 178 (69.0) 468 (37.4)
 Analgesics (n, %) 2555 (89.1) 67 (83.8) 278 (92.7) 33 (82.5) 512 (86.2) 232 (89.9) 1140 (91.1)
 ACT (n, %) 1994 (69.5) 35 (43.8) 294 (98.0) 16 (40.0) 496 (83.5) 121 (46.9) 1155 (92.3)
 Non-ACT antimalarial 210 (7.3) 1 (1.2) 7 (2.3) 1 (2.5) 110 (18.5) 20 (7.8) 267 (21.3)